National Resilience, Inc., a leading biomanufacturing CDMO, is moving its corporate headquarters from San Diego to Blue Ash, Ohio, consolidating its growing footprint in the Cincinnati region. This relocation brings executive leadership closer to the company’s expanding sterile manufacturing and drug product operations, signaling a strategic shift for medical aesthetics supply-chain buyers who rely on domestic sterile injectables and device assembly capacity.
Market signal
Resilience’s new headquarters at 10901 Kenwood Road anchors a regional network exceeding one million square feet across Blue Ash and West Chester. The company’s existing 580,000-square-foot drug product facility in West Chester will be complemented by a 450,000-square-foot packaging, device assembly, and cold storage operation in Blue Ash. This integrated hub spans sterile fill/finish, inspection, assembly, labeling, and distribution, adding approximately 200 jobs in Blue Ash.
Why it matters for buyers
For importers and distributors of sterile injectables and medical aesthetic devices, this move underscores a broader trend of advanced manufacturing shifting from coastal markets to regions like Ohio, where workforce availability and cost structures are more favorable. By co-locating leadership with production, Resilience is doubling down on U.S.-based supply chain resilience, particularly for complex medicines and sterile injectables critical to the aesthetics sector.
Sourcing context
Resilience is aligning corporate operations with specialized production across two sites. In Blue Ash, the company is building large-scale secondary manufacturing capabilities, including visual inspection, device assembly, packaging, labeling, and cold-chain warehousing. In West Chester, a new multi-purpose injectable fill/finish line from Groninger is expanding core manufacturing capacity to support multiple drug formats and commercial production for biopharma partners.
Regulatory and channel signals
“Ohio offers a strong manufacturing workforce, operational infrastructure, and proximity to many customers and partners,” said William Marth, president and CEO of Resilience. “Establishing our headquarters in Blue Ash alongside continued investment in our sterile manufacturing and packaging capabilities positions us to better support the evolving needs of the industry.” JobsOhio President and CEO J.P. Nauseef called the move a signal of the state’s growing strength in pharmaceutical manufacturing, bolstering the nation’s healthcare supply chain.
What buyers should watch
This relocation builds on a 2025 expansion of Resilience’s Ohio operations and signals a long-term strategy to centralize both leadership and production in the region. For medical aesthetics buyers, the enhanced sterile fill/finish and device assembly capacity in Ohio could offer more reliable, domestic sourcing options for injectables and combination products, reducing reliance on overseas supply chains.
Source: Read the original report | Published: June 18, 2026